Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA CAR-T cells (Sorrento Therapeutics)
- Development stage
- Unknown
- Lead developer
- Sorrento Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intraperitoneal
01
Overview
Anti-CEA CAR-T cells (Sorrento Therapeutics) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target cells expressing carcinoembryonic antigen (CEA). CEA is a cell surface glycoprotein that is frequently overexpressed in various adenocarcinomas, including colorectal, pancreatic, gastric, and breast cancers. The therapy involves the genetic modification of a patient's own T cells to express a CAR construct specific for CEA. These engineered T cells are expanded ex vivo and then re-introduced into the patient via intraperitoneal infusion. This localized delivery method is specifically intended to treat peritoneal carcinomatosis, peritoneal metastases, and malignant ascites by allowing the CAR-T cells to directly interact with tumor deposits within the peritoneal cavity, potentially increasing local efficacy while minimizing systemic toxicities.
- Other names
- anti-CEA CAR-T cellsCEA CAR-Tanti-CEA intraperitoneal CAR-T infusions
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)HLA-A (HLA class I histocompatibility antigen A alpha chain)
Beyond the preview
Go deeper on anti-CEA CAR-T cells (Sorrento Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEA CAR-T cells (Sorrento Therapeutics).